Pharming Presents Positive Phase II Topline Data for Leniolisib
Pharming presented positive topline data from its Phase II trial of leniolisib in genetically identifiable primary immunodeficiencies.
Leiden, the Netherlands, October 14, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today presented positive topline data from its Phase II trial of leniolisib in genetically identifiable primary immunodeficiencie…